KR20250108763A - 키메라 및 인간화된 항-인간 ｃｔｌａ４ 단클론 항체 및 이의 용도 - Google Patents

키메라 및 인간화된 항-인간 ｃｔｌａ４ 단클론 항체 및 이의 용도

Info

Publication number
KR20250108763A
KR20250108763A KR1020257022200A KR20257022200A KR20250108763A KR 20250108763 A KR20250108763 A KR 20250108763A KR 1020257022200 A KR1020257022200 A KR 1020257022200A KR 20257022200 A KR20257022200 A KR 20257022200A KR 20250108763 A KR20250108763 A KR 20250108763A
Authority
KR
South Korea
Prior art keywords
ser
val
leu
thr
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257022200A
Other languages
English (en)
Korean (ko)
Inventor
양 리우
판 쩡
마틴 데븐포트
Original Assignee
온코씨4, 아이앤씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코씨4, 아이앤씨. filed Critical 온코씨4, 아이앤씨.
Publication of KR20250108763A publication Critical patent/KR20250108763A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020257022200A 2015-12-15 2016-12-14 키메라 및 인간화된 항-인간 ｃｔｌａ４ 단클론 항체 및 이의 용도 Pending KR20250108763A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562267735P 2015-12-15 2015-12-15
US62/267,735 2015-12-15
US201662309169P 2016-03-16 2016-03-16
US62/309,169 2016-03-16
US201662359036P 2016-07-06 2016-07-06
US62/359,036 2016-07-06
KR1020187017368A KR102830926B1 (ko) 2015-12-15 2016-12-14 키메라 및 인간화된 항-인간 ｃｔｌａ４ 단클론 항체 및 이의 용도
PCT/US2016/066698 WO2017106372A1 (en) 2015-12-15 2016-12-14 Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187017368A Division KR102830926B1 (ko) 2015-12-15 2016-12-14 키메라 및 인간화된 항-인간 ｃｔｌａ４ 단클론 항체 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20250108763A true KR20250108763A (ko) 2025-07-15

Family

ID=59057509

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187017368A Active KR102830926B1 (ko) 2015-12-15 2016-12-14 키메라 및 인간화된 항-인간 ｃｔｌａ４ 단클론 항체 및 이의 용도
KR1020257022200A Pending KR20250108763A (ko) 2015-12-15 2016-12-14 키메라 및 인간화된 항-인간 ｃｔｌａ４ 단클론 항체 및 이의 용도

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020187017368A Active KR102830926B1 (ko) 2015-12-15 2016-12-14 키메라 및 인간화된 항-인간 ｃｔｌａ４ 단클론 항체 및 이의 용도

Country Status (26)

Country Link
US (3) US10618960B2 (enExample)
EP (2) EP3389699B1 (enExample)
JP (4) JP6858779B2 (enExample)
KR (2) KR102830926B1 (enExample)
CN (2) CN108430499B (enExample)
AU (2) AU2016370648B2 (enExample)
BR (1) BR112018012113A2 (enExample)
CA (1) CA3006984C (enExample)
DK (1) DK3389699T5 (enExample)
ES (1) ES2979210T3 (enExample)
FI (1) FI3389699T3 (enExample)
HR (1) HRP20240719T1 (enExample)
HU (1) HUE066907T2 (enExample)
IL (3) IL296354B2 (enExample)
LT (1) LT3389699T (enExample)
MX (3) MX2018006925A (enExample)
MY (1) MY186974A (enExample)
PL (1) PL3389699T3 (enExample)
PT (1) PT3389699T (enExample)
RS (1) RS65703B1 (enExample)
SG (1) SG11201804969PA (enExample)
SI (1) SI3389699T1 (enExample)
SM (1) SMT202400211T1 (enExample)
TW (1) TWI739781B (enExample)
WO (1) WO2017106372A1 (enExample)
ZA (1) ZA201804077B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10144779B2 (en) 2015-05-29 2018-12-04 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
EP4667012A2 (en) 2016-09-19 2025-12-24 OncoC4, Inc. Cd80 and cd86 binding protein compositions and uses thereof
MA50949B1 (fr) 2016-12-07 2023-12-29 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et leurs procédés d'utilisation
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
AU2018366199A1 (en) * 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
SG11202007017PA (en) * 2018-02-02 2020-08-28 Oncoimmune Inc Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
WO2019148444A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
JP2021511812A (ja) * 2018-02-02 2021-05-13 オンコイミューン， インコーポレイテッド がん治療のためのより安全でより効果的な抗ｃｔｌａ４抗体を選択及び設計する方法
WO2019233413A1 (en) 2018-06-05 2019-12-12 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Dimer and use thereof
EP3617230A1 (en) * 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
CA3123338A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
CN114008071B (zh) * 2018-12-27 2025-01-21 吉加根公司 抗ctla-4结合蛋白及其使用方法
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ｏｓｅ免疫治療公司 包含il-7變體之雙官能分子
JP7440724B2 (ja) * 2020-04-13 2024-02-29 ビオシオン インコーポレイテッド Ｃｔｌａ４に結合する抗体及びその使用
JP2023523823A (ja) 2020-05-01 2023-06-07 カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー タンパク質の精製の改善されたプロセス
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2022169269A1 (ko) * 2021-02-03 2022-08-11 주식회사 유틸렉스 항 ctla-4 항체 및 이의 용도
IL307419A (en) 2021-04-09 2023-12-01 Ose Immunotherapeutics A new scaffold for bifunctional molecules with improved properties
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
JP7345889B2 (ja) * 2021-06-17 2023-09-19 株式会社ニューギン 遊技機
AU2022361768A1 (en) * 2021-10-08 2024-05-02 Kashiv Biosciences, Llc Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
WO2023057994A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
WO2023070502A1 (zh) * 2021-10-29 2023-05-04 天辰生物医药(苏州)有限公司 分离的抗原结合蛋白及其用途
MX2024004429A (es) 2021-10-29 2024-05-06 Oncoc4 Inc Regimenes de dosificacion del anticuerpo anti-ctla-4.
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
JP2025525886A (ja) 2022-08-02 2025-08-07 オーエスイー・イミュノセラピューティクス Ｃｄ２８に対する多機能性分子
CN119947752A (zh) 2022-09-16 2025-05-06 昂科医药 抗ctla-4抗体用于治疗腺样囊性癌的用途
WO2024194605A1 (en) 2023-03-17 2024-09-26 Quell Therapeutics Limited Treg therapy
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024227176A1 (en) 2023-04-28 2024-10-31 OncoC4, Inc. Combinations of anti-ctla-4 antibodies and anti-pd-1 antibodies and therapeutic uses thereof
WO2024254403A2 (en) * 2023-06-09 2024-12-12 The Regents Of The University Of California Methods for identifying and correcting tumor humoral immune dysfunction
WO2025133186A1 (en) 2023-12-22 2025-06-26 OncoC4, Inc. Anti-ctla-4 antibody for treatment of patients with prostate cancer and combination therapy with a radioligand therapeutic agent
WO2025201659A1 (en) 2024-03-28 2025-10-02 BioNTech SE Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
AU784062B2 (en) 1999-08-23 2006-01-19 Dana-Farber Cancer Institute, Inc. Novel B7-4 molecules and uses therefor
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
PT1234031T (pt) 1999-11-30 2017-06-26 Mayo Foundation B7-h1, uma nova molécula imunoregulatória
US7034121B2 (en) * 2000-01-27 2006-04-25 Genetics Institue, Llc Antibodies against CTLA4
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
US20090252741A1 (en) * 2004-09-08 2009-10-08 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
EP1793857A4 (en) * 2004-09-08 2008-09-03 Univ Ohio State Res Found COMBINED THERAPY USING ANTI-CTLA4 ANTI-4-1BB ANTIBODIES
WO2006044717A2 (en) 2004-10-15 2006-04-27 Verisign, Inc. One time password
ES2565543T3 (es) 2005-01-24 2016-04-05 Board Of Regents, The University Of Texas System Construcciones de fusión a Fc de unión a fosfatidilserina y su uso terapéutico
EP2439273B1 (en) * 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US8062852B2 (en) 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
CN101628940B (zh) * 2008-07-15 2011-11-23 中国科学院生物物理研究所 一种单克隆抗体及其应用
GB0903325D0 (en) * 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
WO2013142796A2 (en) * 2012-03-23 2013-09-26 Bristol-Myers Squibb Company Methods of treatments using ctla4 antibodies
SMT201900242T1 (it) * 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104292334B (zh) * 2014-04-25 2018-11-27 河南省健康伟业生物医药研究股份有限公司 一种全人源抗ctla-4单克隆抗体、制备方法及应用
EP4667012A2 (en) 2016-09-19 2025-12-24 OncoC4, Inc. Cd80 and cd86 binding protein compositions and uses thereof

Also Published As

Publication number Publication date
MX2025001300A (es) 2025-03-07
SMT202400211T1 (it) 2024-07-09
BR112018012113A2 (pt) 2018-12-04
MX2018006925A (es) 2018-08-01
AU2023203169B2 (en) 2025-11-27
NZ743013A (en) 2025-03-28
IL259988B2 (en) 2023-02-01
FI3389699T3 (fi) 2024-05-28
AU2023203169A1 (en) 2023-06-15
PT3389699T (pt) 2024-06-04
CN108430499B (zh) 2022-07-19
JP2019510733A (ja) 2019-04-18
HUE066907T2 (hu) 2024-09-28
EP3389699B1 (en) 2024-05-01
JP2022123049A (ja) 2022-08-23
MX2025001302A (es) 2025-03-07
IL259988B (en) 2022-10-01
SG11201804969PA (en) 2018-07-30
RS65703B1 (sr) 2024-07-31
TW201731877A (zh) 2017-09-16
KR102830926B1 (ko) 2025-07-08
MY186974A (en) 2021-08-26
IL296354A (en) 2022-11-01
IL296354B1 (en) 2024-03-01
SI3389699T1 (sl) 2024-07-31
CA3006984A1 (en) 2017-06-22
HRP20240719T1 (hr) 2024-09-13
US20200283526A1 (en) 2020-09-10
EP4374926A3 (en) 2024-08-07
DK3389699T5 (da) 2024-09-23
EP4374926A2 (en) 2024-05-29
WO2017106372A1 (en) 2017-06-22
ZA201804077B (en) 2019-09-25
JP2025160458A (ja) 2025-10-22
JP2021100957A (ja) 2021-07-08
US20190127468A1 (en) 2019-05-02
US20230391870A1 (en) 2023-12-07
CN108430499A (zh) 2018-08-21
US10618960B2 (en) 2020-04-14
CN116063492A (zh) 2023-05-05
US12473362B2 (en) 2025-11-18
EP3389699A4 (en) 2019-07-10
JP2023106547A (ja) 2023-08-01
IL259988A (en) 2018-07-31
AU2016370648A1 (en) 2018-06-21
TWI739781B (zh) 2021-09-21
DK3389699T3 (da) 2024-05-13
IL296354B2 (en) 2024-07-01
JP7286845B2 (ja) 2023-06-05
PL3389699T3 (pl) 2024-07-22
EP3389699A1 (en) 2018-10-24
US11629188B2 (en) 2023-04-18
LT3389699T (lt) 2024-06-10
CA3006984C (en) 2023-10-17
AU2016370648B2 (en) 2023-03-09
IL310404A (en) 2024-03-01
ES2979210T3 (es) 2024-09-24
KR20180086219A (ko) 2018-07-30
JP6858779B2 (ja) 2021-04-14

Similar Documents

Publication Publication Date Title
US12473362B2 (en) Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
KR20190130137A (ko) 종양 특이적 세포 고갈을 위한 fc-최적화된 항-cd25
US20240218067A1 (en) Anti-siglec compositions and uses thereof
JP7790837B2 (ja) キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用
HK40110941A (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
HK1259883A1 (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
HK1259883B (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
EA038617B1 (ru) Химерные и гуманизированные античеловеческие ctla-4 моноклональные антитела и их использование
EA049996B1 (ru) Антитело к siglec-10 (варианты)

Legal Events

Date Code Title Description
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)